upneeq Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Upneeq, and when can generic versions of Upneeq launch?
Upneeq is a drug marketed by Rvl Pharms and is included in one NDA. There are twelve patents protecting this drug.
This drug has fifty-one patent family members in twenty-eight countries.
The generic ingredient in UPNEEQ is oxymetazoline hydrochloride. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the oxymetazoline hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Upneeq
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for upneeq?
- What are the global sales for upneeq?
- What is Average Wholesale Price for upneeq?
Summary for upneeq
| International Patents: | 51 |
| US Patents: | 12 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 69 |
| Clinical Trials: | 2 |
| Patent Applications: | 1,937 |
| What excipients (inactive ingredients) are in upneeq? | upneeq excipients list |
| DailyMed Link: | upneeq at DailyMed |
Recent Clinical Trials for upneeq
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Milton S. Hershey Medical Center | Phase 3 |
| University of Miami | Phase 4 |
Pharmacology for upneeq
| Drug Class | Vasoconstrictor |
| Physiological Effect | Increased Sympathetic Activity Vasoconstriction |
US Patents and Regulatory Information for upneeq
upneeq is protected by twelve US patents.
Patents protecting upneeq
Compositions and methods for treating ocular disorders
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING BLEPHAROPTOSIS
Oxymetazoline compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Oxymetazoline compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions and methods for non-surgical treatment of ptosis
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING BLEPHAROPTOSIS
Compositions and methods for treating ocular disorders
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING BLEPHAROPTOSIS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Oxymetazoline compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions and methods for treating ocular disorders
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING BLEPHAROPTOSIS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING BLEPHAROPTOSIS
Compositions and methods for non-surgical treatment of ptosis
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING BLEPHAROPTOSIS
Compositions and methods for non-surgical treatment of Ptosis
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING BLEPHAROPTOSIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rvl Pharms | UPNEEQ | oxymetazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 212520-001 | Jul 8, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Rvl Pharms | UPNEEQ | oxymetazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 212520-001 | Jul 8, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Rvl Pharms | UPNEEQ | oxymetazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 212520-001 | Jul 8, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Rvl Pharms | UPNEEQ | oxymetazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 212520-001 | Jul 8, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Rvl Pharms | UPNEEQ | oxymetazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 212520-001 | Jul 8, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Rvl Pharms | UPNEEQ | oxymetazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 212520-001 | Jul 8, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for upneeq
When does loss-of-exclusivity occur for upneeq?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 20268329
Patent: Oxymetazoline compositions and methods for treating ocular disorders
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2021022404
Patent: Composições de oximetazolina e métodos para tratamento de distúrbios oculares
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 39443
Patent: COMPOSITIONS D'OXYMETAZOLINE ET PROCEDES DE TRAITEMENT DE TROUBLES OCULAIRES (OXYMETAZOLINE COMPOSITIONS AND METHODS FOR TREATING OCULAR DISORDERS)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 21002918
Patent: Composiciones y métodos de oximetazolina para el tratamiento de trastornos oculares
Estimated Expiration: ⤷ Sign Up
China
Patent: 1888326
Patent: 羟甲唑啉组合物和用于治疗眼障碍的方法 (Compositions and methods for treating ocular disorders)
Estimated Expiration: ⤷ Sign Up
Patent: 7045596
Patent: 羟甲唑啉组合物和用于治疗眼障碍的方法 (Oxymetazoline compositions and methods for treating ocular disorders)
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 21015265
Patent: Composiciones y métodos de oximetazolina para el tratamiento de trastornos oculares
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 65737
Patent: COMPOSITIONS D'OXYMÉTAZOLINE ET PROCÉDÉS DE TRAITEMENT DE TROUBLES OCULAIRES (OXYMETAZOLINE COMPOSITIONS AND METHODS FOR TREATING OCULAR DISORDERS)
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 7831
Patent: תרכובות אוקסימטזולין ושיטות לטיפול במחלות עיניים (Oxymetazoline compositions and methods for treating ocular disorders)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 41420
Estimated Expiration: ⤷ Sign Up
Patent: 20183373
Patent: 眼疾患を処置するためのオキシメタゾリン組成物および方法 (OXYMETAZOLINE COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES)
Estimated Expiration: ⤷ Sign Up
Patent: 21191802
Patent: 眼疾患を処置するためのオキシメタゾリン組成物および方法 (OXYMETAZOLINE COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES)
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 21013516
Patent: COMPOSICIONES Y MÉTODOS DE OXIMETAZOLINA PARA EL TRATAMIENTO DE TRASTORNOS OCULARES. (OXYMETAZOLINE COMPOSITIONS AND METHODS FOR TREATING OCULAR DISORDERS.)
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 895
Patent: COMPOSITIONS D'OXYMÉTAZOLINE ET PROCÉDÉS DE TRAITEMENT DE TROUBLES OCULAIRES
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 220384
Patent: COMPOSICIONES Y METODOS DE OXIMETAZOLINA PARA EL TRATAMIENTO DE TRASTORNOS OCULARES
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 202112272T
Patent: OXYMETAZOLINE COMPOSITIONS AND METHODS FOR TREATING OCULAR DISORDERS
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 2108950
Patent: OXYMETAZOLINE COMPOSITIONS AND METHODS FOR TREATING OCULAR DISORDERS
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 2410503
Estimated Expiration: ⤷ Sign Up
Patent: 200128629
Patent: 안구 장애를 치료하기 위한 옥시메타졸린 조성물 및 방법 (Oxymetazoline Compositions and Methods for Treating Ocular Disorders)
Estimated Expiration: ⤷ Sign Up
Patent: 220084264
Patent: 안구 장애를 치료하기 위한 옥시메타졸린 조성물 및 방법 (Oxymetazoline Compositions and Methods for Treating Ocular Disorders)
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering upneeq around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Lithuania | 2680829 | ⤷ Sign Up | |
| World Intellectual Property Organization (WIPO) | 2012118704 | ⤷ Sign Up | |
| South Korea | 20240060580 | 안구 장애를 치료하기 위한 옥시메타졸린 조성물 및 방법 (Oxymetazoline Compositions and Methods for Treating Ocular Disorders) | ⤷ Sign Up |
| Singapore | 192801 | COMPOSITIONS AND METHODS FOR NON-SURGICAL TREATMENT OF PTOSIS | ⤷ Sign Up |
| Japan | 7141420 | ⤷ Sign Up | |
| European Patent Office | 2680829 | COMPOSITIONS ET UTILISATIONS POUR LE TRAITEMENT NON-CHIRURGICAL DE LA PTOSIS (COMPOSITIONS AND METHODS FOR NON-SURGICAL TREATMENT OF PTOSIS) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
